​

Prelude Therapeutics (PRLD) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

PRLD Stock Forecast


Prelude Therapeutics (PRLD) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $8.00, with a high of $8.00 and a low of $8.00. This represents a 140.96% increase from the last price of $3.32.

$1 $2 $3 $4 $5 $6 $7 $8 High: $8 Avg: $8 Low: $8 Last Closed Price: $3.32

PRLD Stock Rating


Prelude Therapeutics stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (62.50%), 1 Hold (12.50%), 2 Sell (25.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 2 1 5 Strong Sell Sell Hold Buy Strong Buy

PRLD Price Target Upside V Benchmarks


TypeNameUpside
StockPrelude Therapeutics140.96%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends


1M3M12M
# Anlaysts--1
Avg Price Target--$8.00
Last Closing Price$3.32$3.32$3.32
Upside/Downside--140.96%
Ratings Trends

DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 2623---5
Oct, 2623---5
Sep, 2612---3
Aug, 2612---3
Jul, 2612---3
Analyst Price Target Forecasts

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 27, 2026H.C. Wainwright$8.00$4.7070.21%140.96%
Sep 10, 2024Robert BurnsH.C. Wainwright$5.00$5.17-3.29%50.60%
Jun 20, 2024Peter LawsonBarclays$3.00$3.87-22.48%-9.64%
Mar 13, 2024Reni BenjaminJMP Securities$7.00$4.6251.52%110.84%
Nov 17, 2022H.C. Wainwright$15.00$7.7094.81%351.81%
Nov 15, 2022Morgan Stanley$10.00$8.1023.46%201.20%
Analyst Rating Forecasts

DateCompanyPrevious RatingNew RatingRating Change
Oct 14, 2026CitigroupMarket OutperformMarket Outperformhold
Oct 13, 2026H.C. WainwrightBuyBuyhold
Jul 15, 2026H.C. WainwrightBuyBuyhold
Apr 27, 2026H.C. WainwrightBuyBuyhold
Sep 19, 2024H.C. WainwrightNeutralBuyupgrade
Sep 10, 2024H.C. WainwrightNeutralNeutralhold
Jun 20, 2024BarclaysEqual-WeightUnderweightdowngrade
Dec 19, 2023Morgan StanleyEqual-WeightUnderweightdowngrade
Nov 15, 2022Morgan StanleyEqual-WeightEqual-Weighthold
Feb 28, 2022BarclaysEqual-Weightdowngrade

Financial Forecast


EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.02$-1.68$-1.29---
Avg Forecast$-2.04$-1.78$-1.50$-1.26$-1.37$-1.26
High Forecast$-2.01$-1.74$-1.30$-1.18$-1.28$-1.26
Low Forecast$-2.06$-1.83$-1.68$-1.33$-1.46$-1.26
Surprise %-0.98%-5.62%-14.00%---

Revenue Forecast

$5M $12M $19M $26M $33M $40M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$7.00M$12.14M---
Avg Forecast-$2.00M-$8.30M$21.70M$37.88M
High Forecast-$2.00M-$8.30M$21.70M$37.88M
Low Forecast-$2.00M-$8.30M$21.70M$37.88M
Surprise %-250.00%----

Net Income Forecast

$-130M $-118M $-106M $-94M $-82M $-70M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-121.83M$-127.17M$-99.50M---
Avg Forecast$-121.83M$-107.73M$-89.89M$-75.85M$-82.69M$-76.05M
High Forecast$-121.33M$-104.77M$-78.40M$-71.39M$-77.22M$-76.05M
Low Forecast$-124.33M$-110.69M$-101.37M$-80.31M$-88.16M$-76.05M
Surprise %-18.05%10.69%---

PRLD Forecast FAQ


Is Prelude Therapeutics stock a buy?

Prelude Therapeutics stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 1 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Prelude Therapeutics is a favorable investment for most analysts.

What is Prelude Therapeutics's price target?

Prelude Therapeutics's price target, set by 8 Wall Street analysts, averages $8 over the next 12 months. The price target range spans from $8 at the low end to $8 at the high end, suggesting a potential 140.96% change from the previous closing price of $3.32.

How does Prelude Therapeutics stock forecast compare to its benchmarks?

Prelude Therapeutics's stock forecast shows a 140.96% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Prelude Therapeutics over the past three months?

  • November 2026: 40.00% Strong Buy, 60.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2026: 40.00% Strong Buy, 60.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Prelude Therapeutics’s EPS forecast?

Prelude Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.26, marking a -2.33% decrease from the reported $-1.29 in 2025. Estimates for the following years are $-1.37 in 2027, and $-1.26 in 2028.

What is Prelude Therapeutics’s revenue forecast?

Prelude Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $8.3M, reflecting a -31.63% decrease from the reported $12.14M in 2025. The forecast for 2027 is $21.7M, and $37.88M for 2028.

What is Prelude Therapeutics’s net income forecast?

Prelude Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-75.849M, representing a -23.77% decrease from the reported $-99.498M in 2025. Projections indicate $-82.689M in 2027, and $-76.05M in 2028.